Published Online:9 May 2013https://doi.org/10.2217/nnm.13.68
Abstract
Over the last three decades many first-generation nanomedicines have successfully entered routine clinical use and it is now important for medicines regulatory agencies to consider the mechanisms needed to ensure safe introduction of ‘follow-on’ nanomedicine products, ‘nanosimilars’. Moreover, drug regulators need to ensure that ‘next’-generation nanomedicines enter clinical development and consequently the market in a safe and timely way for the benefit of public health. Here we review recent European Medicines Agency activities that relate to the effective development and evaluation of nanomedicine products while keeping patient and consumer safety at the forefront.
Keywords:
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Hamburg MA. FDA’s approach to regulation of products of nanotechnology. Science336(6079),299–300 (2012).Crossref, Medline, CAS, Google Scholar
- 2 Gaspar R. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. Nanomedicine (Lond.)2(2),143–147 (2007).Link, CAS, Google Scholar
- 3 Tyner K, Sadrieh N. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Methods Mol. Biol.697,17–31 (2011).Crossref, Medline, CAS, Google Scholar
- 4 Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharmaceutics8(6),2101–2141 (2011).▪▪ Comprehensive overview of state-of-the-art nanomedicines with lists of products in clinical use and development.Crossref, Medline, CAS, Google Scholar
- 5 EU Scientific Committee on Emerging and Newly Identified Health Risks. Scientific Basis for the Definition of the Term ‘Nanomaterial’. European Commission, Brussels, Belgium (2010).Google Scholar
- 6 Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma8(1),21–32 (2008).▪▪ Comprehensive overview of the rationale for the design and clinical use of PEGylated liposomal doxorubicin.Crossref, Medline, Google Scholar
- 7 Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am. Soc. Hematol. Educ. Program2010,338–347 (2010).▪▪ Important overview of the history, pharmacology, administration, efficacy and toxicity of intravenous iron.Crossref, Medline, Google Scholar
- 8 Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine3(3),295–310 (2008).Medline, CAS, Google Scholar
- 9 Farrell D, Ptak K, Panaro NJ, Grodzinski P. Nanotechnology- based cancer therapeutics-promise and challenge-lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm. Res.28(2),273–278 (2011).▪ Discusses emerging anticancer nanomedicines and their development in clinical testing.Crossref, Medline, CAS, Google Scholar
- 10 Schellekens H, Klinger E, Mühlebach S, Brin JF, Storm G, Crommelin DJ. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol.59(1),176–183 (2011).Crossref, Medline, CAS, Google Scholar
- 11 Nyström AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J. Control. Release161(2),403–408 (2012).Crossref, Medline, Google Scholar
- 12 Fadeel B, Garcia-Bennett AE. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv. Drug Deliv. Rev.62,362–374 (2010).Crossref, Medline, CAS, Google Scholar
- 13 Duncan R. Nanomedicine(s) and their regulation: an overview. In: Safety Assessment of Nanomaterials: Implications for Nanomedicine. Fadeel B (Ed.). Pan Stanford Publishing, Singapore (2013) (In Press).▪ Discusses the regulation of nanomedicines and the important distinction between nanomedicine safety and nanomaterial toxicity.Google Scholar
- 14 Linkov I, Satterstrom K, Corey L. Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine4,167–171 (2008).Crossref, Medline, CAS, Google Scholar
- 15 Matsumura Y. Polymeric micellar delivery systems in oncology. Jpn J. Clin. Oncol.38(12),793–802 (2008).Crossref, Medline, Google Scholar
- 16 Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin. Microbiol. Infect.14(Suppl. 4),25–36 (2008).Crossref, Medline, CAS, Google Scholar
- 17 Barenholz Y. Doxil® – first FDA-approved nano-drug: lessons learned. J. Control. Release60(2),117–134 (2012).Crossref, Google Scholar
- 18 MacDougall IC. Evolution of iv iron compounds over the last century. J. Ren. Care35(Suppl. 2),8–13 (2009).Crossref, Medline, Google Scholar
- 19 Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin. J. Am. Soc. Nephrol.1(Suppl. 1),S19–S23 (2006).Crossref, Medline, CAS, Google Scholar
- 20 Garneata L. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? J. Ren. Nutr.18(1),40–45 (2008).Crossref, Medline, Google Scholar
- 21 Snodin D. EMA reflection paper on generic nanoparticle iron products: a case of bias by omission? In: Scrip Regulatory Affairs. Informa UK, London, UK (2011).Google Scholar
- 22 Lima BS. EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications. In: Scrip Regulatory Affairs. Informa UK, London, UK (2011).Google Scholar
- 23 Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev.47(1),113–131 (2012).Crossref, Google Scholar
- 24 Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res.27(12),2569–2589 (2010).Crossref, Medline, CAS, Google Scholar
- 25 Munster PN, Miller K, Krop IE et al. A Phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer. Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2012 (Abstract TPS663).Google Scholar
- 101 European Medicines Agency. Reflection Paper on nanotechnology-based medicinal products for human use. www.ema.europa.euGoogle Scholar
- 102 European Medicines Agency. A FDA perspective on nanomedicine current initiatives in the US. www.ema.europa.eu/docs/en_GB/document_library/Presentation/2010/09/WC500096201.pdfGoogle Scholar
- 103 Commission Recommendation of 18 October 2011 on the definition of nanomaterial. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:275:0038:0040:EN:PDFGoogle Scholar
- 104 European Medicines Agency. The European Medicines Agency publishes a full scientific assessment report called a European public assessment report (EPAR) for every medicine granted a central marketing authorisation by the European Commission. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124Google Scholar
- 105 European Medicines Agency. European Medicines Agency’s workshop on nanomedicines. www.ema.europa.euGoogle Scholar
- 106 European Medicines Agency. European Medicines Agency’s workshop on nanomedicines. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001108.jsp&mid=WC0b01ac058004d5c1Google Scholar
- 107 European Medicines Agency. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140351.pdfGoogle Scholar
- 108 European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdfGoogle Scholar
- 109 European Medicines Agency. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/02/WC500138390.pdfGoogle Scholar
- 110 European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdfGoogle Scholar
